Use of erythropoietin, active vitamin D3 metabolites, and alkali agents in predialysis patients

Seminars in Nephrology

Volumn 17, Issue 4, 1997, Pages 270-284

  Ismail, Nuhad ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICARBONATE; CALCITRIOL; ERYTHROPOIETIN; VITAMIN D;

ANEMIA; CHILD GROWTH; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DIALYSIS; HYPERTENSION; KIDNEY FUNCTION; METABOLIC ACIDOSIS; NITROGEN BALANCE; OSTEOMALACIA; OSTEOPOROSIS; PATHOGENESIS; PRIORITY JOURNAL;

ACIDOSIS; ADULT; ANEMIA; ANIMALS; CALCITRIOL; CALCIUM COMPOUNDS; CHOLECALCIFEROL; ERGOCALCIFEROLS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; KIDNEY FAILURE, CHRONIC; RATS; RENAL DIALYSIS; RENAL OSTEODYSTROPHY;

EID: 0030836556     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (112)

1. Erslev AJ: Humoral regulation of red cell production. Blood 8:349-387, 1953
2. Jacobson LO, Woldwasser E, Fried W, Plzak L: Role of the kidney in erythropoiesis. Nature 179:633-634, 1957
3. Miyake T, Kung CKH, Goldwasser E: Purification of human erythropoietin. J Biol Chem 252:5558-5564, 1977
4. Lin FK, Suggs S, Lin CH, Browne JK, et al: Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci USA 82:7580-7585, 1985
5. Eschbach JW, Adamson JW: Anemia of end-stage renal disease (ESRD). Kidney Int 28:1-5, 1985
6. Wallner SF, Vautrin RM: Evidence that inhibition of erythropoiesis is important in the anemia of chronic renal failure. J Lab Clin Med 97:170-178, 1981
7. McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW: Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 25:437-444, 1984
8. The US Recombinant Human Erythropoietin Predialysis Study Group: Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 18:50-59, 1991
9. Roth D, Smith RD, Schulman G, et al: Effects of recom-binant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24:777-784, 1994
10. Hakim RM, Lazarus JM: Biochemical parameters in chronic renal failure. Am J Kidney Dis 11:238-247, 1988
11. Eschbach J\V, Kelley MR, Haley NR, et al: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158-163, 1989
12. Lim VS, DeGowin RL, Zavala D, et al: Recombinant human erythropoietin treatment in predialysis patients: A double-blind placebo-controlled trial. Ann Intern Med 110:108-114, 1989
13. Watson AJ, Gimenez LF, Cotton S, et al: Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med 89:432-435, 1990
14. Stone WJ, Graber SE, Krantz SB, et al: Treatment of the anemia of predialysis patients with recombinant human erythropoietin: A randomized, placebo-controlled trial. Am J Med Sci 31:171-179, 1988
15. Pincus T, Olsen NJ, Russel J, et al: Multicenter study of rccombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 89:161-168, 1990
16. Ludwig H, Fritz E, Kotzmann H, et al: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 322:1693-1699, 1990
17. Fischl M, Galpin JE, Levine JD, et al: Recombinant human erythropoietin for patients with AIDS treated with Zidovudine. N Engl J Med 322:1693-1699, 1990
18. Raine AEG: Effects of erythropoietin on blood pressure. Am J Kidney Dis 18:76-83, 1991 (suppl 1)
19. Duke M, Abelmann W: The haemodynamic response to chronic anemia. Circulation 40:493-500, 1969
20. Raine AEG: Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: Implications of erythropoietin therapy. Lancet 1:97-100, 1988
21. Carlini R, Obialo CL, Rothstein M: Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens6:103-107, 1993
22. Schiffel H: Correlation of blood pressure in end-stage renal disease with platelet cytosolic free calcium concentration during treatment of renal anemia with recombinant human erythropoietin. Artif Kidney Dialysis 15:343-348, 1992
23. Anderson S: Effects of Erythropoietin in predialysis patients. Am J Kidney Dis 17:103-106, 1991
24. De Wardner HE, McSwiney RR, Miles BE: Renal hemodynamics in primary polycythemia. Lancet 2:204-206, 1951
25. Wilcox CS, Payne J, Harrison BDW: Renal function in patients with chronic hypoxemia and cor pulmonale following reversal of polycythemia. Nephron 30:173-177, 1982
26. Myers BD, Deen WM, Robertson CR, Brenner BM: Dynamics of glomerular ultrafiltration in the rat VIII. Effects of hematocrit. Circ Res 36:425-435, 1975
27. Garcia DL, Anderson S, Rennke HG, Brenner BM: Anemia lessens and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci USA 85:6142-6146, 1988
28. Lafferty HM, Garcia DL, Rennke HG, et al: Anemia ameliorates progressive renal injury in experimental DOCA-Salt hypertension. J Am Soc Nephrol 1:1180-1185, 1991
29. de Jong PE, Weening JJ, Donker AJM, et al: The effect of phlebotomy on renal function and proteinuria in a patient with congenital cyanotic heart disease. Nephron 33:225-226, 1983
30. Sklar AH, Chaudhary BA: Reversible proteinuria in obstructive sleep apnea syndrome. Arch Intern Med 148:87, 1988
31. Simpson LO: Blood viscosity induced proteinuria. Nephron 36:280-281, 1984
32. Spear OS: The glomerulus in cyanotic congenital heart disease and primary pulmonary hypertension: A review. Nephron 1:238-248, 1964
33. Austrian Multicenter Study Group of r-HuEPO in Predialysis Patients: Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Nephron 61:399-403, 1992
34. Kleinman KS, Schweitzer SU, Perdue ST, et al: The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: A double-blind, placebo-controlled trial. Am J Kidney Dis 14:486-495, 1989
35. Abraham PA, Opsahl JA, Rachael KM, et al: Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol 10:128-136, 1990
36. Muirhead N, Cattran DC, Zaltzman J, et al: Safety and efficacy of recombinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction. J Am Soc Nephrol 5:1216-1222, 1994
37. Onoyama K, Kumagai H, Takeda K, et al: Effects of human recombinant erythropoietin on anaemia, systemic haemodynamics and renal function in predialysis renal failure patients. Nephrol Dial Transplant 4:966-970, 1989
38. Frenken LAM, Verberckmoes R, Michielsen P, Koene RAP: Efficacy and tolerance of treatment with recombinant-human erythropoietin in chronic renal failure (pre-dialysis) patients. Nephrol Dial Transplant 4:782-786, 1989
39. Lim VS, DeGowin RL, Zavala D, et al: Recombinant human erythropoietin treatment in pre-dialysis patients. Ann Intern Med 110:108-114, 1989
40. Traindl O, Franz M, Kovarik J: Recombinant human erythropoietin (rhEPO) in patients with chronic renal insufficiency in the predialysis period. Kidney Int 37:551, 1990
41. Levin A, Singer J, Thompson R, et al: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27:347-354, 1996
42. Levy D, Garrison RJ, Savage DD, et al: Prognostic implications of echocardiographically determined left ventricular mass in the framingham heart study. N Engl J Med 322:1561-1566, 1990
43. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36:286-290, 1989
44. Foley RN, Parfrey PS, Harriett JD: Left ventricular hypertrophy in dialysis patients. Semin Dialysis 5:34-41, 1992
45. Foley RN, Parfrey PS, Harriett JD, et al: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47:186-192, 1995
46. Eschbach JW, Aquiling T, Haley NR, et al: The longterm effects of recombinant human erythropoietin on the cardiovascular system. Clin Nephrol 38:S98-S103, 1992
47. Malluche HH, Ritz E, Lange HP, et al: Bone histology in incipient and advanced renal failure. Kidney Int 9:355-362, 1976
48. Cundy T, Hand DJ, Oliver DO, et al: Who gets renal bone disease before beginning dialysis? Br Med J 290:271-275, 1985
49. Tessitore N, Bonucci E, D'Angelo A, et al: Bone histology and calcium metabolism in patients with nephrotic syndrome and normal or reduced renal function. Nephron 37:153-159, 1984
50. Kanis JA, Cundy T, Hamdy NAT: Renal osteodystrophy. Baillieres Clin Endocrinol Metab 2:193-241, 1988
51. Hamdy NAT, Kanis JA, Beneton MNC, et al: Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. Br Med J 310:358-363, 1995
52. 3 administration in moderate renal failure: A prospective double-blind trial. Kidney Int 35:661-669, 1989
53. Hernandez D, Concepcion MT, Lorenzo V, et al: Adynamic bone disease with negative aluminium staining in predialysis patients: Prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 9:517-523, 1994
54. Hercz G, Pei Y, Greenwood C, et al: Aplastic osteodystrophy without aluminum: The role of suppressed parathyroid function. Kidney Int 44:860-866, 1993
55. Drucke TB: The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 48:259-272, 1995
56. Llach F: Secondary hyperparathyroidism in renal failure: The trade-off hypothesis revisited. Am J Kidney Dis 25:663-679, 1995
57. Portale AA, Booth BE, Tsai H, Morris RC: Reduced plasma concentration of 1,25 dihydroxyvitamin D in children with moderate renal insufficiency. Kidney Int 21:627-632, 1982
58. 2D. Kidney Int 27:565-573, 1985
59. 3 may be responsible for the development of hyperparathyroidism in early chronic renal failure. Proc EDTA 22:1124-1128, 1985
60. 3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremie patients. J Clin Invest 92:1436-1443, 1993
61. Silver J, Moallem E, Epstein E, et al: New aspects in the control of parathyroid hormone secretion. Nephrol Hypertens 3:379-385, 1994
62. 3 in predialysis chronic renal failure. Contrib Nephrol 90:183-188, 1991
63. Tougaard L, Sorensen E, Brochner-Mortensen J, et al: Controlled trial of 1α-hydroxycholecalciferol in chronic renal failure. Lancet 1:1044-1047, 1976
64. Nordal KP, Dahl E: Low dose calcitriol versus placebo in patients with predialysis chronic renal failure. J Clin Endocrinol Metabol 67:929-936, 1988
65. Eke FU, Winterborn MH: Effect of low dose 1 α-hydroxycholecalciferol on glomerular filtration rate in moderate renal failure. Arch Dis Child 58:810-813, 1984
66. Bertoli M, Luisetto G, Ruffatti A, et al: Renal function during calcitriol therapy in chronic renal failure. Clin Nephrol 33:98-102, 1990
67. Christiansen C, Rodbro P, Christensen MS, et al: Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxychoIecalciferol. Lancet 2:700-703, 1978
68. 3 treatment of non-dialyzed patients with chronic renal failure. Effects on bone, mineral metabolism and kidney function. Clin Nephrol 13:103-108, 1980
69. Pierides AM, Ellis HA, Simpson W, et al: The effect of la-hydroxy vitamin D3 in predialysis renal bone disease. Clin Endocrinol 7:1095-116S, 1977
70. 3 in childhood renal osteodystrophy. N Engl J Med 298:238-242, 1978
71. Chan JCM, McEnery PT, Chinchilli VM, et al: A prospective, double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol verses dihydrotachysterol. J Pediatr 124:520-528, 1994
72. Torres A, Lorenzo V, Hernandez D, et al: Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTH. Kidney Int 47:1434-1442, 1995
73. 3 in early renal failure. Ann Rev Med 43:227-237, 1992
74. 3] harmful to renal function? JAMA 242:1875-1876, 1979
75. Madias NE, Kraut JA: Uremic acidosis, in Seidin DW, Giebisch G (eds): The Regulation of Acid-Base Balance, New York, NY, Raven Press, Ltd., 1989, pp 285-317
76. Kopple JD: Abnormal amino acid and protein metabolism in uremia. Kidney Int 14:340-348, 1978
77. Price SR, Mitch WE: Metabolic acidosis and uremic toxicity: Protein and amino acid metabolism. Semin Nephrol 14:232-237, 1994
78. Ikizler TA, Greene J, Wingard RL, et al: Spontaneous dietary protein intake during progression of chronic renal failure. J Am Soc Nephrol 6:1386-1391, 1995
79. May RC, Kelly RA, Mitch WE: Mechanisms for defects in muscle protein metabolism in rats with chronic uremia. Influence of metabolic acidosis. J Clin Invest 79:1099-1103, 1987
80. Mitch WE, Medina R, Grieber S, et al: Metabolie acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes. J Clin Invest 93:2127-2133, 1994
81. Bailey JL, Wang X, England BK, et al: The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest 97:1447-1453, 1996
82. Ballmer PE, McNurlan MA, Hulter HN, et al: Chronic metabolic acidosis decreases albumin synthesis and induces negative nitrogen balance in humans. J Clin Invest 95:39-45, 1995
83. May RC, Hara Y, Kelly RA, et al: Branched-chain amino acid metabolism in rat muscle: Abnormal regulation in acidosis. Am J Physiol 252:E712-E718, 1987
84. Blom Van Assendelft PM, Dorhout Mees EJ: Urea metabolism in patients with chronic renal failure: Influence of sodium bicarbonate or sodium chloride administration. Metabol Clin Exp 19:1053-1063, 1970
85. McSherry E, Morris RC: Attainment of normal stature with alkli therapy in infants and children with classic renal tubular acidosis. J Clin Invest 61:509-514, 1978
86. Papadoyannakis NJ, Stefanides CJ, McGeown M: The effect of the correction of metabolic acidosis on nitrogen and protein balance of patients with chronic renal failure. Am J Clin Nutr 40:623-627, 1984
87. Williams B, Hattersley J, Layward E, et al: Metabolic acidosis and skeletal muscle adaptation to low protein diets in chronic uremia. Kidney Int 40:779-798, 1991
88. Mochizuki T: The effect of metabolic acidosis on amino and keto acid metabolism in chronic renal failure. Jpn J Nephrol 33:213, 1991
89. Reaich D, Channon SM, Scrimgeour CM, et al: Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation. Am J Physiol 263:E735-E739, 1992
90. Reaich D, Channon SM, Scrimgeour CM, et al: Correction of acidosis in humans with CRF decreases protein degradation and amino acid oxidation. Am J Physiol 265:E230-E235, 1993
91. Garibotto G, Paoletti E, Fiorini F, et al: Peripheral metabolism of branched-chain keto acids in patients with chronic renal failure. Miner Electrolyte Metab 19:25-31, 1993
92. Lemann J Jr, Litzow JR, Lennon EJ: Studies of the mechanism by which chronic metabolic acidosis augments urinary calcium excretion in man. J Clin Invest 46:1318-1328, 1967
93. Bushinsky DA, Kreiger NS, Geisser I, et al: Effect of pH on bone calcium and proton fluxes in vitro. Am J Physiol 245:F-204-F209, 1983
94. Kraut JA, Mishler DR, Singer FR, Goodman WG: The effects of metabolic acidosis on bone formation and bone resorption in the rat. Kidney Int 30:694-700, 1986
95. Kraut JA: The role of metabolic acidosis in the pathogenesis of renal osteodystrophy. Adv Renal Repl Therapy 2:40-51, 1995
96. Jaffe HL, Bodansky A, Chandler JP: Ammonium chloride decalcification as modified by calcium intake: The relation between generalized osteoporosis and ostitis fibrosa. J Exp Med 56:823-834, 1932
97. Barzel US, Jowsey J: The effect of chronic acid and alkali administration on bone turnover in adult rats. Clin Sci 36:517-524, 1969
98. Kaye M: The effect in the rat of varying intakes of dietary calcium, phosphorous, and hydrogen ion on hyperparathyroidism due to chronic renal failure. J Clin Invest 53:256-260, 1974
99. Chan YL, Sardie E, Mason RS, et al: The effect of metabolic acidosis on vitamin D metabolites and bone histology in uremic rats. Calcif Tiss Int 37:158-164, 1985
100. Visser WJ, Roelofs JM, Dursma SA: Effect on bone of administering sodium bicarbonate to uremic rats. Miner Electrolyte Metab 2:274-275, 1979
101. Pines KL, Mudge GH: Renal tubular acidosis with osteomalacia. Am J Med 11:302-311, 1951
102. Cochran M, Wilkinson R: Effect of correction of metabolic acidosis on bone mineralization rates in patients with renal osteomalacia. Nephron 15:98-110, 1975
103. Perry W, Alien LN, Stamp TCB, et al: Vitamin D resistance in osteomalacia after ureterosigmoidostomy. N Engl J Med 20:1110-1112, 1977
104. Richards P, Chamerland MJ, Wrong OM: Treatment of osteomalacia of renal tubular acidosis by sodium bicarbonate alone. Lancet 2:994-997, 1972
105. McSherry E, Morris RC Jr: Attainment and maintenance of normal stature with alkali therapy in infants and children with classic renal tubular acidosis. J Clin Invest 61:509-527, 1978
106. Mora Palma FJ, Ellis HA, Cook DB, et al: Osteomalacia in patients with chronic renal failure before dialysis or transplantation. Q J Med 52:332-348, 1983
107. Lefebvre A, De Vemejoul MC, Gueris J, et al: Opti-mal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 36:1112-1118, 1989
108. Mitchell JH, Wildenlhal K, Johnson RL Jr: The effects of acid-base distrubances on cardiovascular and pulmonary function. Kidney Int 1:375-389, 1972
109. Karins RG, Jones ER, Stom MC, et al: Diagnostic strategies in disorders of fluid, electrolyte and acid-base homeostasis. Am J Med 3:496-520, 1982
110. Sharpey-Schafer EP: Venous constriction after exercise; its relation to acid-base changes in venous blood. Clin Sci 29:397, 1965
111. Marsiglis JC: Relevance of beta receptor blockade to the negative inotropic effect induced by metabolic acidosis. Cardiovasc Res 7:225, 1973
112. 3 and NaCl tolerance in chronic renal failure. Clin Nephrol 7:21-25, 1977